ASCO 2022 | Pertuzumab, trastuzumab and cyclophosphamide in older patients with HER2+ breast cancer

Whilst the Phase III CLEOPATRA (NCT00567190) and Phase II EMILIA trials (NCT00829166) demonstrated the efficacy of trastuzumab and trastuzumab emtansine respectively in HER2+ breast cancer, elderly patients remain underrepresented in these type of clinical trials. Thomas Meyskens, MD, PhD, EORTCKU Leuven, Leuven, Belgium, gives an overview of long-term follow-up data from the Phase II EORTC 75111 trial (NCT01597414) of pertuzumab and trastuzumab with or without cyclophosphamide in elderly patients with HER2+ breast cancer. Addition of cyclophosphamide did not increase toxicity and overall survival as well as progression-free survival remained superior in the cohort that received cyclophosphamide. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.